Molecular diagnostic solutions provider BioGX has launched its portable pixl qPCR real-time PCR platform Ex-US with an expanded test menu for infectious diseases.

The benchtop four-channel, 16-well real-time PCR platform supports testing of up to 16 samples in a single batch.

It shows the integrated results on a device with the compact footprint of a touchpad.

The system comprises four-optical channel direct imaging fluorescence, a fast Peltier-powered thermal cycler, and an ultra-low-light complementary metal oxide semiconductor (CMOS) bio-imager sensor to enable accurate and reliable molecular diagnostic testing.

It has been designed for applications where minimal space, portability and quick turnaround times are needed.

BioGX noted that the pixl instrument can be used with the company’s CE-IVD marked assays, including Xfree COVID-19 (N1/RdRp), Flu A, Flu B; Xfree Group A Streptococcus; and Xfree COVID-19 (N1-gene) Direct RT-PCR.

This launch enables global access for pixl and also complements the recently received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the expanded use of Xfree COVID-19 Direct RT-PCR on the pixl platform.

BioGX CEO Shazi Iqbal said: “pixl, combined with our unique Xfree chemistry, offers a low-cost direct-sample-to-answer PCR solution on a portable, compact device.

“pixl will provide broader access to clinical laboratories for decentralised PCR testing, enabling faster, better, low-cost near-patient molecular diagnostics.”

The company intends to make additional syndromic tests from its lyophilized multiplex assays menu available on the pixl platform from next January.

These assays include the research use only (RUO) direct-sample assays Xfree HSV1/HSV2/VZV, Xfree Human Monkeypox (hMPXV), and Xfree Treponema pallidum (Syphilis).